Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

Original reporting
Published Oct 14, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$DXR
Bullish
high confidence
Mentioned
$DXR
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DXRBullishMed
01

Why it matters

The disclosed clinical data provides the first public evidence of BVA's clinical utility, a catalyst that could shift analyst expectations and drive short‑term price movement.

02

Market read

New clinical evidence may lift Daxor's stock as investors reassess growth prospects in the cardiac‑care device market.

03

What to watch

Reimbursement rates and adoption speed in hospitals are uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Daxor (NASDAQ:DXR) is a medical‑device company specializing in blood‑volume analysis, a niche but FDA‑cleared diagnostic market.

Company-level read

Ticker impact

$DXRBullishHigh confidence
Context

Daxor presented new clinical data on its FDA-cleared blood volume analysis (BVA) technology at the HFA 2026 meeting, showing diagnostic benefits in heart‑failure patients.

Expected impact

upward pressure as investors price in potential sales growth from the new clinical evidence

Evidence & confidence

The studies are the first public disclosure of efficacy, a material catalyst for a niche medical‑device company.

Market effects

May increase interest in blood‑volume diagnostic devices and related cardiac‑care suppliers.

U.S. medical‑device sector could see modest uplift.

Limited to niche cardiac‑care market; no broad macro effect.

Counterpoint

If larger competitors launch similar technology, Daxor's advantage could be short‑lived.

Key entities

  • Daxor Corporation

    Issuer of the BVA diagnostic system.

  • Heart Failure Society of America

    Venue where the data were presented.

Related articles

$DXRMedAI 8/10

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$NSRXMed

Nasus Pharma presents phase 2 data on intranasal epinephrine

Nasus Pharma (NYSE:NSRX) presented Phase 2 study data for NS002, an intranasal epinephrine powder, showing faster therapeutic threshold reach than autoinjectors. No serious adverse events were reported. The company plans a pivotal study by late 2026, with results expected in Q1 2027. NS002 is being developed as a needle-free alternative for anaphylaxis treatment.